VOL NO REGD NO DA 1589

Sunday, February 20, 2005

Headline

News Watch

Trade & Finance

Editorial

World/Asia

Metro/Country

Corporate/Stock

Sports

 

FE Specials

FE Education

Young World

Growth of SMEs

Urban Property

Monthly Roundup

Business Review

FE IT

Saturday Feature

Asia/South Asia

 

Feature

44th National Day of the State of Kuwait

National Day of Brunei Darussalam

National Day of Australia

Asia Pharma Expo-2005

 

 

 

Archive

Site Search

 

HOME

CORPORATE/STOCK
 
corporate watch
Beximco Pharma’s anti-smoking drug hits market
2/20/2005
 

          Beximco Pharmaceuticals Limited has launched Zybexo SR (Bupropion hydrochloride 150 mg, sustained release tablet) tablet in the city recently, which is a highly effective supportive therapy for giving up smoking. Bupropion is the most prescribed smoking cessation therapy all over the world and approved by the USFDA. Bupropion is superior to nicotine patch and highly effective for previously attempted smokers. Zybexo SR should be taken according to physician's advice. It is now available in chemist's shops in the country. — FE Report

 

 
  More Headline
All indices fall
Gainers dominate losers
Dow climb puts 11,000 in traders' sights
Hyundai reaps rich dividends from planned image lift
EXIM Bank holds managers' conference
Wal-Mart's earnings beat Street's forecast
GM not worried about China’s overcapacity
Pakistan stocks to soar next week
Tokyo might tighten stock trading rules
Exxon world's most valuable public co
Qwest hopes new bid will bring MCI back to table
Beximco Pharma’s anti-smoking drug hits market
Former Boeing director gets jail term
  
 

Print this page | Mail this page | Save this page | Make this page my home page

About us  |  Contact us  |  Editor's panel  |  Career opportunity | Web Mail

 

 

 

 

Copy right @ financialexpress.com